Le terutroban (S18886) est un antagoniste spécifique des récepteurs à la thromboxane.
() b
~J
INTRODUCTION
Reactive hyperemia (or synonymously postischemic vasodilation) refers to the transient vasodilation taking place in many tissues when perfusion is reestablished after a short interruption. In man, reactive hyperemia is relatively simple to evaluate in forearm muscle and skin, where reliable noninvasive methods exist for the measurement of blood flow (respectively, strain-gauge plethysmography and laser Doppler flowmetry), whereas transient ischemia can be obtained easily by the inflation at suprasystolic pressure of a pneumatic 1 • 2 Severa! studies have indicated that, recorded in this way, reactive hyperemia is linked to and thus could be used as a surrogate marker for cardiovascular risk.
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11 However, one obstacle to such use might be the fact that many subjects at increased cardiovascular risk receive cyclooxygenase (COX) inhibitors, with a potential confounding influence on the measured vascular responses.
COX catalyzes the transformation of arachidonic acid to prostaglandin H2, a common initial step that then leads, through multiple downstream pathways, to the formation of several biologically active compounds collectively termed prostanoids. There are essentially 2 isoforms of COX, COX-1, and COX-2, each coded by a different gene. Both can be found in a wide array of tissues, including the vascular endothelium and vascular smooth muscle. 12 Classically, the expression of COX-1 is constitutional, whereas COX-2 is induced by inflammation, but the presence ofCOX-2 has also been described in the absence ofinflammatory stimulus, notably in endothelial cells. 12 In humans, the development of hypertension seems associated with a shift in prostanoid production from predominant control by COX-1 to predominant control by COX-2. 12 Prostanoids exert their biological effects by stimulating at least 5 different types ofreceptors, the IP, DP, EP, FP, and thromboxane prostanoid (TP). 13 Classically, the prostanoid PGI2 (prostacyclin) specifically ligates the IP receptor, leading in blood vessels to vasodilation and inhibition of coagulation, whereas thromboxane A2 (TxA2) stimulates the TP receptors, with the opposite consequences. The increased cardiovascular risk associated with the intake of some phannacological COX inhibitors, such as rofecoxib (selective for COX-2) or diclofenac (nonselective) has been explained by an induced shift in the balance of PGI2 and TxA2 in favor of the latter. 14 • 15 The physiology and pathophysiology of prostanoids is rendered more complex by the fact that some of these compounds may ligate more than 1 receptor type, potentially leading to confiicting effects. A case in point is that of prostaglandin D2, which may stimulate both endothelial DP receptors (leading to endotheliumdependent vasodilation) and vascular smooth muscle TP receptors ( endothelium-independent vasoconstriction). 12 In view of this complexity, it is not surprising that, in healthy humans, the impact of COX inhibitors on the reactive hyperemia of skin 9 • 1 &-21 or forearm muscle 21 -25 has been vaiiable, ranging from marked or modest blunting, 21 -25 no effect, 18 • 19 to marked potentiation. 20 One potential reason for these discrepancies might reside in differences between studies regarding the relative impact of the administered drug on the production of vasoconstrictive versus vasodilator COX products. To examine this possibility, it would be necessary to selectively block the action of vasoconstrictor prostanoids.
In hmnan forerann, a short transient ischemia (3-10 minutes) is followed by an increased concentration in effluent venous blood of thromboxane B2, the stable metabolite of TxA2. 29 Thus, in this vascular territory at least, the stimulation of TP receptors might contribute to limit reactive hyperemia. In the present study, we hypothesized that administration to healthy volunteers of S 18886 (terutroban), a selective antagonist of TP receptors, 30 • 31 would enhance reactive hyperemia in forearm skin and muscle.
MATERIALS AND METHODS

Subjects
All participants were fully informed about the protocol of the study and gave their written consent. The study confonned to the principles outlined in the Declaration of Helsinki and was approved by the institutional review board and by the Swiss regulatory authorities (Swissmedic ).
The study took place from April 5, 2007 , to November 21, 2007 . Twenty white male healthy subjects, aged 18-30 years, were enrolled. Inclusion criteria were an inconspicuous medical history without bleeding disorder, no remarkable findings on clinical examination, and normal results on the following laboratory tests: blood cell count, potassium, sodium, calcium, creatinine, total protein, glucose, liver, pancreatic, and coagulation (prothrombin time, partial prothromboplastin time, fibrinogen, and platelet function), platelet function assessed with the PFA-100 System (Siemens Healthcare, Erlangen, Germany). Additional requirements were negative serology for hepatitis B and C virus and HN, normal electrocardiogram, negative urine analysis for blood (dispstick), and drugs (minimal test).
Exclusion criteria were a planned strenuous activity during the study period, surgery in the 3 months before the study or planned during the study, excessive use of alcohol (>45 g/d), excessive intake of caffeine beverage (~5 cups/ d or ~500 mg of caffeine/d), use of any addictive substance, regular use of agents suppressing gastric acidity, and use any drugs affecting hemostasis in the 10 days preceding inclusion (anticoagulant agents, antiplatelet drugs, steroidal and nonsteroidal anti-inflammatory drugs, and drug containing salicylates).
Assessment of Reactive Hyperemia
Reactive hyperemia was elicited in the forearm by temporarily occluding the ipsilateral brachial artery with a standard size pneumatic cuff placed around the upper ann and inflated above systolic pressure (200 mm Hg). For skin assessment, occlusion times of3 minutes and then 30 seconds were used, with 5 minutes of reperfusion allowed in between. For muscle assessment, the occlusion time was 5 minutes. Separate maneuveurs were carried out on the dominant side and the nondominant side for the recording of reactive hyperemia in forearm muscle and forearm skin, respectively.
Foreann muscle blood flow was assessed using venous occlusion strain-gauge plethysmography (Hokanson, Bellevue, W A), with the hand excluded by means of an pneumatic cuff 128 1 www.jcvp.org inflated around the wrist, as described previously. 21 Skin blood flow was measured on the volar face of the forearm, using a laser Doppler imager (LDI; Moor Instruments, Axminster, United Kingdom), as described previously.
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Study Design and Protocol
The study was single center, placebo controlled, crossover, and triple blinded (participants, investigators, and data collector). For each participant, the sequence of treatment (active drug first or placebo first) was randomly assigned at inclusion. To ensure that the treatrnent was given blindly after randomization, tablets ofidentical appearance containing either placebo or the active drug were prepared by the Institut de Recherches internationales Servier (Courbevoie, France) and sent to our center. The active drug was the TxA2 receptor blocker S 18886 (terutroban), 30 milligrams per tablet.
The complete protocol comprised 1 selection and 4 investigation sessions. The various eligibility and exclusion criteria were checked on the selection session and rechecked 7 days later on investigation session 1 (Fig. lA) . Randomization took place on investigation session 1. The first treatrnent period lasted from investigation session 1 to investigation session 2, 5 days later. A washout period of 10-15 days followed. The second treatrnent period then started on investigation session 3 and lasted 5 additional days, until investigation session 4. A single tablet containing Sl8886 30 mg or placebo was administered on each day of each treatment period, at 8:00 AM. To guarantee treatment compliance, the subjects had to report daily to the laboratory in the early morning, so that one investigator could hand over the appropriate tablet and verify its actual ingestion.
Investigation
Starting from the selection session and for the entire duration of study, the subjects were instructed to avoid all the following: use any drugs affecting hemostasis (anticoagulant agents, antiplatelet drugs, steroidal and nonsteroidal antiinftammatory drugs, and drug containing salicylates), use of any addictive substance, and use of agents suppressing gash·ic acidity. An additional requirement was to avoid any intake of caffeine beverage in the 24 hours preceding each session.
On each investigation session, reactive hyperemia in skin and muscle was examined immediately before and 2 hours after drug intake. In Figure lB , these examinations are designated as Hyl (beginning of treatment period, immediately before intake of the first tablet), Hy2 (2 hours after intake of :first tablet), Hy3 (fifth day of treatment period, immediately before intake of the fifth tablet), and Hy4 (2 hours after intake offifth tablet). The timing ofHy2 relative to Hyl and Hy4 relative to Hy3 was based on the known pharmacodynamies of Sl8886. A single oral 30 mg dose of this drug affects maximal inhibition of platelet aggregation, starting after 30 minutes and maintained for at least 12 hours. 30, 31 · All investigations took place in a quiet room with air conditioning. Ambient temperature was kept between 21°C and 23.5°C. The subjects were examined in the supine position with arms supported by a cushion. On each vascular investigation, each type of reactive hyperemia (forearm muscle and foreann skin) was determined in triplicate, allowing 10 minutes between deftation of the ann cuff used for arterial occlusion and its next inflation. Detenninations in foreann muscle were carried out first, on the dominant arm, and were followed by those in forearm skin, on the contralateral side.
Data Analysis
The recorded hyperemic response was summarized as (1) the baseline blood ftow (ie, immediately before arterial occlusion), (2) the peak blood ftow observed after release of aiierial occlusion and (3) the area under curve, as previously described. 21 Statistical analysis was carried out with mixed model analysis of variance, using treatment (placebo or 
RESULTS
The demographic and hemodynamic characteristics of the remaining 20 subjects are shown in Table 1 displayed in Figure 2 . Identical results were obtained on the first examination of each treatment sequence (Hyl ), irrespective of whether placebo or active drng was subsequently received. In both treatment sequences, a slight but statistically significant increase in baseline flow (P = 0.016) and area under curve (P = 0.02), but not peak flow, was noted 2 hours after ingestion of the first tablet (Hy2 vs. Hy 1 ). A similar albeit not statistically significant trend occurred on the last day of each treatment sequence (ie, Hy4 vs. Hy2). The difference in baseline flow between Hy4 and Hy 1 was statistically significant (P = 0.029). Most importantly, when compared with placebo, active treatment had no discernible effect on forearm muscle reactive hyperemia, at any tune point (Hy2, Hy3, and Hy4).
The results regarding reactive hyperemia in forearm skin were essentially superilnposable with those in foreann muscle, except for the absence of time-dependent effects. Again, there was no detectable influence of Sl8886, whether reactive hyperemia followed a 3-minute occlusion (Fig. 3) or 30-second occlusion (data not shown).
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DISCUSSION W e present here the first study assessing the impact of TP receptor blockade on reactive hyperemia. Our results do not support any major modulation by TP receptor activation of the reactive hyperemia triggered by shmt periods of ischemia in the foreann skin and skeletal muscle microcirculation of young healthy humans.
In humans, several authors have explored the potential mediation of reactive hyperemia by vasoactive prostanoids, using the same investigation methods as in the present work and inhibition of COX with nonsteroidal anti-inflammatmy agents (AINS) as pharmacological tools. As mentioned in the Introduction, and displayed more accurately in Table 2 , results have been variable and at tune inconsistent. When present at ail, the observed effects of AINS administered systemically were toward a reduced amplitude and/or duration of postischemic vasodilation in muscle and skin. In contrast with these observations stands the study by Medow et al, 20 who used microdialysis to locally expose the calf skin of healthy volunteers to the AINS ketorolac and as a result observed a 2-fold amplification of reactive hyperemia. Because of the large concentration of ketorolac perfused into the microdialysis catheter (10 mM), these authors probably achieved higher tissue drng levels and thus more complete COX inhibition than was possible with systemic administration. The heterogeneity ofresults shown in Table 1 might thus be explained by differences between studies in the degree of COX inhibition, leading to different impacts on the balance of vasodilator and vasoconstrictor prostanoids. If this hypothesis is correct, then the data by Medow et al 20 would implicate vasoconstrictor prostanoids as major moderators ofreactive hyperemia, at least in the skin.
TxA2 is a major vasoconstrictor product of the COX pathway and, as reviewed in the Introduction, its production in human foreann appears stimulated by periods of ischemia as short (3-10 minutes) as carried out in the present study (skin 3 minutes, muscle 5 minutes). In these vascular beds, therefore, we anticipated that antagonizing the binding of TxA2 to its specific TP receptor with Sl8886 would enhance postischemic vasodilation. This hypothesis was however not confirmed by our findings, which did not show any observable effect of Sl8886 onreactivehyperemia in the forearm (Figs. 2, 3) , suggesting a lack of influence ofTxA2 on this physiological process.
One might argue that such a negative outcome might be related to an insufficient power of our study, due to the small size of the study population. However, a post hoc analysis carried out to verify this point indicated that, with the present design and 20 subjects included, power was ;::::Q.8 to detect a ;::::JO% effect of treatment on either skin or muscle reactive hyperemia, had it been present on at least 1 of the 3 postdrng examinations. Thus, if our study missed an Îlnpact of Sl8886, as administered, on postischemic vasodilation, such impact is liloely to be only minor.
A second issue to be considered is that of dosage and bioavailability of the study drng. Drng intake took place in the systematic presence of the investigator, so that treatment compliance was not in doubt. Sl8886 was administered orally as a single dose of 30 milligrams per day for 5 days. Measurements at Hy2 and Hy4 took place 2 hours after drng intake, a timing chosen because it corresponds to the tüne to reach peak plasma level after a single oral dose, as shown in detail in pharmacokinetic data of healthy volunteers. 30 In these studies, furthermore, the concentrations obtained after intake of a 30-mg tablet remained for at least 6 hours above 400 µ,g/L ( ""==' 1 nM), a concentration shown to effectively block the vasoconstriction induced by U46619, a TP receptor agonist, in an ex vivo model. 32 In addition, 2 studies showed the ability of a single oral dose of 10 mg S 18886 to improve ftow-mediated vasodilation when evaluated 2 hours after drug intake in patients with high cardiovascular risk and evidence of endothelial dysfunction. 33 • 34 Taken together, these data make it very unlikely that our negative results could be explained by insufficient tissue concentration of the TP receptor antagonist.
If efficient tissue concentrations of Sl8886 were reached in our conditions, the negative results imply either that vasoconstrictor prostanoids did not in fact modulate the observed postischemic responses or that they did via pathways distinct from TP receptor signaling. The first possibility would run counter to the evidence, cited in the Introduction, that ischemia as shmt as carried out here markedly increases the production of TxA2 in human forearm. However, this evidence cornes from mostly ancient studies having assessed thromboxane B2 (the stable metabolite of TxA2) with immunoassays 2 6-29 and whose results could not be replicated with more specific methods based on gas chromatography-tandem mass spectrometry. 35 lt remains that the previously mentioned marked augmentation of reactive hyperemia by the local blockade of COX (using microdialysis for drug administration)2° is a strong argument in favor of a modulatory influence of vasoconstrictor prostanoids, at least in the skin. Such influence could be exe1ted by eicosanoids distinct from TxA2, able to stimulate non-TP receptors that would be insensitive to S 18886. The family of prostanoid receptors comprises multiple members, 13 of which not only the TP but also the EPl, 36 EP3, 37 and FP 38 types are able to mediate the contraction of vascular smooth muscle. Further work would be required to determine whether reactive hyperemia in human forearm tissue is modulated by eicosanoid ligands to these additional receptors, such as prostaglandin E2 (EPl and EP3) or prostaglandin F2a (FP). 
CONCLUSIONS
Blockade of the TP receptor with S 18886 did not affect the reactive hyperemia elicited by a sho1t period of ischemia in the forearm muscle and skin ofyoung healthy male humans. Because the importance of vasoconstrictive prostanoids increases with aging, 39 it remains to be determined whether a similar conclusion holds in older subjects. Fmther studies are anyway required to detennine the pathways whereby COX products modulate postischemic vasodilation.
